Biotechnology firm Alector said that its pivotal phase 3 trial of the investigational antibody latozinemab (AL001) in individuals with Frontotemporal dementia due to GRN mutation (FTD-GRN) did not meet its clinical co-primary endpoint of slowing disease progression as measured by the Clinical Dementia Rating® plus NACC FTLD-Sum of Boxes (CDR® + NACC FTLD-SB) over 96 weeks. The company said the trial did achieve a statistically significant increase in plasma progranulin (PGRN) concentrations, the biomarker co-primary endpoint.
Secondary and exploratory endpoints, including fluid biomarkers and volumetric MRI, showed no treatment-related effects, according to the company. The open-label extension and continuation study for latozinemab will be discontinued.
Alector said that as of 30 September 2025 it had approximately US $291.1 million in cash, cash equivalents and short-term investments, which it expects will provide a runway through 2027. The company is reducing its workforce by about 49 % and announced that President & Head of R&D Sara Kenkare-Mitra will resign effective 22 December 2025.
The company stated its development focus will shift to its ongoing collaboration with GSK on the investigational antibody AL101 (GSK4527226) in early Alzheimer’s disease, as well as its proprietary Alector Brain Carrier (ABC) blood-brain-barrier platform, with IND submissions targeted for its ABC-enabled candidates AL137 in 2026 and AL050 in 2027.
Alector described the outcome as disappointing but emphasised that the data will inform further understanding of progranulin biology and FTD pathophysiology.
